☆
4.7
Meeting Abstract
A phase II, multicenter, single-arm study of parsaclisib, a PI3K delta inhibitor, in relapsed or refractory follicular lymphoma in China: Updated data from the study.
JOURNAL OF CLINICAL ONCOLOGY (2022)
评价这篇论文
主要评分表示论文的整体质量水平。次要评分独立反映论文的优点或缺点。
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started